Bio-Path Holdings Inc (NASDAQ:BPTH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Monday. The firm currently has a $0.75 price target on the stock. Zacks Investment Research’s target price would suggest a potential downside of 9.87% from the company’s current price.
According to Zacks, “BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path’s drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized. “
Separately, HC Wainwright set a $5.00 price target on shares of Bio-Path Holdings and gave the company a “buy” rating in a research report on Thursday.
Shares of Bio-Path Holdings (NASDAQ:BPTH) traded up 8.0649% during mid-day trading on Monday, reaching $0.8321. 174,606 shares of the company’s stock were exchanged. The firm’s market cap is $79.59 million. Bio-Path Holdings has a 52-week low of $0.70 and a 52-week high of $3.19. The company has a 50 day moving average price of $0.87 and a 200 day moving average price of $1.14.
Bio-Path Holdings (NASDAQ:BPTH) last posted its quarterly earnings results on Wednesday, March 15th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.02. Analysts forecast that Bio-Path Holdings will post ($0.09) earnings per share for the current fiscal year.
var userip;Your IP Address: document.write(userip);
A hedge fund recently raised its stake in Bio-Path Holdings stock. HighTower Advisors LLC boosted its position in Bio-Path Holdings Inc (NASDAQ:BPTH) by 1.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,155,070 shares of the company’s stock after buying an additional 12,000 shares during the period. HighTower Advisors LLC owned approximately 1.21% of Bio-Path Holdings worth $1,617,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 21.00% of the company’s stock.
About Bio-Path Holdings
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bio-Path Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.